| abstract |
The present disclosure provides oligonucleotide compositions that target the covalently closed circular (ccc) DNA of hepatitis B virus (HBV). Also disclosed herein are methods for treating a subject diagnosed with, or suspected of having an HBV infection and/or an HBV-associated disorder, e.g ., chronic hepatitis B infection, liver failure or cirrhosis and hepatocellular carcinoma. |